<?xml version="1.0" encoding="UTF-8"?>
<p>It is recommended that those patients already on statins should continue with therapy if diagnosed with COVID-19, and adherence should be maintained to a suitable dose, according to the patientâ€™s CVD risk. Additionally, based on the above described cholesterol reduction, plaque stabilization, CVD risk prevention, anti-inflammatory, and potential antiviral properties of statins, de novo initiation of statin therapy may be considered in high-risk patients during severe manifestations of COVID-19 to prevent some of the life-threatening cardiovascular complications. </p>
